Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Souza, Ana C. O.; Amaral, Andre C.

Advanced search

Search - Use quotation marks to get a more specific result

Index

Field of knowledge

Start date

Betweenand

(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Full text
Author(s):	Souza, Ana C. O. ; Amaral, Andre C. Total Authors: 2
Document type:	Review article
Source:	FRONTIERS IN MICROBIOLOGY; v. 8, MAR 7 2017.
Web of Science Citations:	9
Abstract
Fungal diseases have been emerging as an important public health problem worldwide with the increase in host predisposition factors due to immunological dysregulations, immunosuppressive and/or anticancer therapy. Antifungal therapy for systemic mycosis is limited, most of times expensive and causes important toxic effects. Nanotechnology has become an interesting strategy to improve efficacy of traditional antifungal drugs, which allows lower toxicity, better biodistribution, and drug targeting, with promising results in vitro and in vivo. In this review, we provide a discussion about conventional antifungal and nanoantifungal therapies for systemic mycosis. (AU)

FAPESP's process:	15/10390-6 - IDENTIFICATION OF PATHOGENIC AND CELL DEATH MECHANISMS DURING INFECTION BY P. brasiliensis AND P. lutzii
Grantee:	Ana Camila Oliveira Souza
Support Opportunities:	Scholarships in Brazil - Post-Doctoral

Short URL